Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

All TrialsIndustry lead sponsorIndustry collaboratorPhase 4

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health

NCT01769040 / 2012-002890-71: Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis

Completed

Europe

Rifaximin, Xifaxan, placebo

Copenhagen University Hospital, Hvidovre, Norgine, Region MidtJylland Denmark, Statens Serum Institut

Liver Cirrhosis, Ascites

01/16

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites